1st Group Enrolled in Trial of uniQure’s AMT-130 Gene Therapy
uniQure has completed patient enrollment for the first group participating in a Phase 1/2 trial assessing the safety and efficacy of AMT-130, its experimental gene therapy for Huntington’s disease…